July 31, 2024 10:27 AM EDT

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial

Katherine Lewin

News Reporter

MacroGenics said it will no longer dose the remaining patients who could have received more in a Phase 2 trial studying its antibody-drug conjugate in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Macro­Gen­ics stops fur­ther dos­ing in Phase 2 prostate can­cer drug tri­al

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial